J&J Says Profit Is Not Important in Developing a Coronavirus Vaccine

The transcript discusses the plans for manufacturing COVID-19 vaccines, addressing potential shortages of vials and stoppers, and the strategy of producing vaccines at risk before approval. It also covers the potential for virus mutations and the need for vaccine adaptation, as well as Johnson & Johnson's commitment to developing vaccines on a non-profit basis.

What is the expected timeline for the availability of the vaccine?

How does the company plan to handle potential mutations of the virus?

What is the company's stance on profit in relation to vaccine development?